Abstract：
OBJECTIVE: There were 82.4 million new gonorrhoea cases worldwide in 2020. Dual treatment with ceftriaxone or cefixime and azithromycin or doxycycline is currently recommended for gonorrhoea in Indonesia. However, reduced susceptibility and resistance to cephalosporins and azithromycin are increasing. We evaluated the susceptibility pattern of Neisseria gonorrhoeae to cefixime, ceftriaxone, azithromycin and doxycycline.
METHODS: N. gonorrhoeae isolates were obtained from 19 male participants with clinically and laboratory-confirmed gonorrhoea. Antibiotic susceptibility testing was conducted by disc diffusion and interpreted according to Clinical and Laboratory Standards Institute and Centers for Disease Control and Prevention criteria.
RESULTS: Reduced susceptibility or resistance was observed against doxycycline in 19 isolates (100%), cefixime in six (31.6%), ceftriaxone in three (15.8%) and azithromycin in zero (0%) isolates.
CONCLUSIONS: A dual treatment regimen with ceftriaxone and azithromycin can still be recommended as first-line therapy for gonorrhoea in Indonesia. Antibiotic susceptibility surveillance of N. gonorrhoeae should be routinely conducted.
METHODS: N. gonorrhoeae isolates were obtained from 19 male participants with clinically and laboratory-confirmed gonorrhoea. Antibiotic susceptibility testing was conducted by disc diffusion and interpreted according to Clinical and Laboratory Standards Institute and Centers for Disease Control and Prevention criteria.
RESULTS: Reduced susceptibility or resistance was observed against doxycycline in 19 isolates (100%), cefixime in six (31.6%), ceftriaxone in three (15.8%) and azithromycin in zero (0%) isolates.
CONCLUSIONS: A dual treatment regimen with ceftriaxone and azithromycin can still be recommended as first-line therapy for gonorrhoea in Indonesia. Antibiotic susceptibility surveillance of N. gonorrhoeae should be routinely conducted.
摘要：
目标：2020年，全球有8240万新的淋病病例。在印度尼西亚，目前推荐使用头孢曲松或头孢克肟和阿奇霉素或强力霉素双重治疗淋病。然而,对头孢菌素和阿奇霉素的敏感性和耐药性降低。我们评估了淋病奈瑟菌对头孢克肟的易感性，头孢曲松,阿奇霉素和强力霉素.
方法：N.淋病分离株来自19例临床和实验室确诊淋病的男性参与者.通过盘扩散进行抗生素敏感性测试，并根据临床和实验室标准研究所以及疾病控制和预防中心的标准进行解释。
结果：在19个分离株（100％）中观察到对多西环素的敏感性或耐药性降低，六中头孢克肟(31.6%)，头孢曲松在三个（15.8％）和阿奇霉素在零（0％）分离。
结论：在印度尼西亚，头孢曲松和阿奇霉素的双重治疗方案仍可推荐作为淋病的一线治疗方案。淋病奈瑟菌的抗生素敏感性监测应常规进行。
方法：N.淋病分离株来自19例临床和实验室确诊淋病的男性参与者.通过盘扩散进行抗生素敏感性测试，并根据临床和实验室标准研究所以及疾病控制和预防中心的标准进行解释。
结果：在19个分离株（100％）中观察到对多西环素的敏感性或耐药性降低，六中头孢克肟(31.6%)，头孢曲松在三个（15.8％）和阿奇霉素在零（0％）分离。
结论：在印度尼西亚，头孢曲松和阿奇霉素的双重治疗方案仍可推荐作为淋病的一线治疗方案。淋病奈瑟菌的抗生素敏感性监测应常规进行。
